IL252042B - Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma - Google Patents

Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma

Info

Publication number
IL252042B
IL252042B IL252042A IL25204217A IL252042B IL 252042 B IL252042 B IL 252042B IL 252042 A IL252042 A IL 252042A IL 25204217 A IL25204217 A IL 25204217A IL 252042 B IL252042 B IL 252042B
Authority
IL
Israel
Prior art keywords
inhibition
treatment
hepatocellular carcinoma
ornithine aminotransferase
gaba analogues
Prior art date
Application number
IL252042A
Other languages
English (en)
Hebrew (he)
Other versions
IL252042A0 (en
Original Assignee
Univ Northwestern
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern, Hadasit Med Res Service filed Critical Univ Northwestern
Publication of IL252042A0 publication Critical patent/IL252042A0/en
Publication of IL252042B publication Critical patent/IL252042B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
IL252042A 2014-11-07 2017-04-30 Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma IL252042B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076980P 2014-11-07 2014-11-07
PCT/US2015/059738 WO2016073983A2 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
IL252042A0 IL252042A0 (en) 2017-06-29
IL252042B true IL252042B (en) 2020-05-31

Family

ID=55910047

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252042A IL252042B (en) 2014-11-07 2017-04-30 Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma

Country Status (9)

Country Link
US (1) US9603820B2 (enExample)
EP (1) EP3215144B1 (enExample)
JP (1) JP6867949B2 (enExample)
AU (1) AU2015342801A1 (enExample)
CA (1) CA2966642C (enExample)
ES (1) ES2882126T3 (enExample)
IL (1) IL252042B (enExample)
MX (1) MX2017006022A (enExample)
WO (1) WO2016073983A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3758693A4 (en) * 2018-03-29 2021-06-02 Ovid Therapeutics Inc. USE OF (1S, 3S) -3-AMINO-4- (DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S) -3-AMINO-4- (DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1 -CARBOXYLIC IN THE TREATMENT OF EYE DISORDERS
US10822301B2 (en) 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
KR20250051780A (ko) 2018-05-25 2025-04-17 노오쓰웨스턴 유니버시티 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의합성을 위한 공정
PL3813816T3 (pl) 2018-06-07 2023-07-31 Ovid Therapeutics Inc. Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x
US11203596B2 (en) 2019-02-25 2021-12-21 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
WO2020206234A1 (en) * 2019-04-03 2020-10-08 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
JP2024510422A (ja) * 2021-03-03 2024-03-07 ノースウェスタン ユニバーシティ ヒトオルニチンアミノトランスフェラーゼの選択的不活化剤としての３－アミノ－４，４－ジハロシクロペンタ－１－エンカルボン酸
EP4326743A1 (en) * 2021-04-20 2024-02-28 BicycleTX Limited Bicyclic peptide ligands specific for p-selectin
CN118401255A (zh) * 2021-08-19 2024-07-26 N1生命股份有限公司 紫杉醇缀合化合物、包含所述化合物的药物组合物及它们的使用方法
WO2024196851A1 (en) * 2023-03-17 2024-09-26 Northwestern University Bicyclic compounds as inactivators of oat and gaba-at

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
IL177609A (en) 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma

Also Published As

Publication number Publication date
CA2966642A1 (en) 2016-05-12
US9603820B2 (en) 2017-03-28
IL252042A0 (en) 2017-06-29
WO2016073983A3 (en) 2016-08-11
AU2015342801A1 (en) 2017-05-18
EP3215144B1 (en) 2021-04-28
EP3215144A2 (en) 2017-09-13
EP3215144A4 (en) 2018-06-20
ES2882126T3 (es) 2021-12-01
JP6867949B2 (ja) 2021-05-12
US20160128958A1 (en) 2016-05-12
MX2017006022A (es) 2017-11-17
CA2966642C (en) 2023-03-28
WO2016073983A2 (en) 2016-05-12
JP2017533964A (ja) 2017-11-16

Similar Documents

Publication Publication Date Title
IL252042B (en) Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma
IL285154A (en) Therapeutic inhibitor of lactate dehydrogenase and their factors
ZA201604272B (en) Inhibitors of glutaminase
IL258516A (en) (s)-3-Amino-4-(difluoromethylnyl)cyclopent-1-en-1-carboxylic acid and related compounds as GABA aminotransferase inhibitors for the treatment of epilepsy, addiction and hepatocellular carcinoma
IL249476A0 (en) Combined treatment with glutaminase inhibitors
SG11201708034SA (en) Methods of administering glutaminase inhibitors
ZA201700183B (en) Acetylcholinesterase inhibitors for treatment of dermatological conditions
EP3107538A4 (en) Combination therapy for hepatocellular carcinoma
SG11201508419PA (en) Compositions and methods for detection and treatment of hepatocellular carcinoma
SG10201407557VA (en) Therapeutic biologic for treatment of hepatocellular carcinoma
IL264950B1 (en) Combined treatments for the treatment of malignant liver cell carcinoma
IL258876B (en) Treatment of fatty liver associated with low ovulation
PT3142641T (pt) Formulações para o tratamento de hipertiroidismo
IL250846A0 (en) Synthesis of cyclocreatin and its analogs
GB201412010D0 (en) Treatment of hypertransaminasemia
PT3131633T (pt) Derivados mmf de etilenogicois
ZA201408372B (en) Therapeutic biologic for treatment of hepatocellular carcinoma
IL250599A0 (en) The composition for the treatment of arthritis and osteoarthritis
GB201513922D0 (en) Treatment of hyperpigmentation
GB201613350D0 (en) Treatment of hyperpigmentation
GB201522936D0 (en) A combination of Chinese medicine treating fatty liver
GB201523020D0 (en) The combination of traditional chinese medicine for the treatment of paronychia
GB201603752D0 (en) Treatment of hypothyroidism
GB201603755D0 (en) Treatment of hypothyroidism
AP2016009662A0 (en) Combination of taurine and racemethionine for treatment of liver diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed